742 related articles for article (PubMed ID: 30116244)
1. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
2. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
Julander JG; Trent DW; Monath TP
Vaccine; 2011 Aug; 29(35):6008-16. PubMed ID: 21718741
[TBL] [Abstract][Full Text] [Related]
3. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
[TBL] [Abstract][Full Text] [Related]
4. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
5. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
7. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
8. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.
Schäfer B; Holzer GW; Joachimsthaler A; Coulibaly S; Schwendinger M; Crowe BA; Kreil TR; Barrett PN; Falkner FG
PLoS One; 2011; 6(9):e24505. PubMed ID: 21931732
[TBL] [Abstract][Full Text] [Related]
12. A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.
Calvert AE; Dixon KL; Piper J; Bennett SL; Thibodeaux BA; Barrett AD; Roehrig JT; Blair CD
Antiviral Res; 2016 Jul; 131():92-9. PubMed ID: 27126613
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
14. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
[TBL] [Abstract][Full Text] [Related]
15. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
[TBL] [Abstract][Full Text] [Related]
16. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
[TBL] [Abstract][Full Text] [Related]
17. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
18. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
19. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
[TBL] [Abstract][Full Text] [Related]
20. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
Front Immunol; 2020; 11():577751. PubMed ID: 33133096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
